---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000009"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T13:33:14.825745+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Recursion Pharmaceuticals amends bylaws to enhance proxy disclosure and conform to Delaware law

## Summary
- Bylaw amendments enhance procedural mechanics and disclosure for stockholder director nominations and proposals (except Rule 14a-8).
- Amendments incorporate universal proxy rules per Rule 14a-19 and conform to recent DGCL changes.
- Updated provisions regarding Board committees, officers, written consent, indemnification, and exclusive forum.
- Compensation recovery policy reflected in limitation on indemnification.
- Effective January 25, 2024; filed as Exhibit 3.1.

## SEC filing metadata
- accession: 0001601830-24-000009
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/0001601830-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/rxrx-20240125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000009
- JSON: https://secwatch.observer/filing/0001601830-24-000009.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000009.txt

## Key facts
- Governance Changes
  RECURSION PHARMACEUTICALS, INC.: Amended and restated Bylaws to enhance stockholder proposal procedures, adopt universal proxy rules, conform to DGCL, update director/officer provisions, and make other revisions (effective 2024-01-25).
  - Change: bylaw amendment
  - Effective: 2024-01-25
  source text: On January 25, 2024, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000009/0001601830-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.